Continuation Study for Latozinemab

Alector

Status and phase

Invitation-only

Phase 3

Conditions

Neurodegenerative Diseases

Treatments

Drug: Latozinemab

Study type

Interventional

Funder types

Industry

Identifiers

NCT06111014

AL001-CS-302

2023-506805-20-00 (Other Identifier)

Details and patient eligibility

About

Continuation study to provide continued access to latozinemab for participants who have previously participated in a latozinemab study

Full description

This is an open-label continuation study to provide access and assess the safety and tolerability of latozinemab in participants who have completed participation in their parent latozinemab study.

All participants will receive open-label latozinemab at a dose of 60/mg/kg, every 4 weeks (q4w).

Enrollment

35 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker).
Has successfully completed participation in their parent latozinemab study.
Female participants must be nonpregnant and nonlactating.
Male participants must agree to acceptable contraception use.

Exclusion criteria

Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins.
Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD.